

# Index

## **ACCELERATED**

### **EXAMINATION**

Generally, **29:1 to 29:6**  
AIA Section 11(h), **29:3**  
AIA Section 25, **29:3**  
Amended statutes, **29:3**  
Congressional intent, **29:2**  
Fee-based revised examination  
conditions, **29:6**  
provisions, **29:5**  
Initial conditions for fee-based  
revised examination, **29:6**  
Non-fee based revised examina-  
tion provisions, **29:4**  
17 C.F.R. 1.17(c), **29:6**  
17 C.F.R. 1.102, **29:6**  
35 U.S.C. Section 2(b), **29:3**  
Track One petitions, USPTO  
statistics on, **29:7**

## **ACT TO CORRECT AND IMPROVE CERTAIN PROVISIONS OF LEAHY-SMITH AMERICA INVENTS ACT**

Text, **App 7**

## **ACTUAL NOTICE**

**Marking** (this index)

## **ADMINISTRATIVE LAW JUDGE**

AIA Section 21, payment of ALJs,  
**31:3**

## **AIA SECTION 3(g)(7)(A, B)**

Funding agreements, **31:2**

## **AIA SECTION 6(a-c)**

**Inter Partes Review** (this index)

## **AIA SECTION 6(d)**

**Post-Grant Review** (this index)

## **AIA SECTION 8(a)**

Pre-issuance submissions, **20:3**

## **AIA SECTION 10**

Fee setting, **25:3**

## **AIA SECTION 11**

Fees, **25:4**

## **AIA SECTION 11(h)**

Accelerated examination, **29:3**

## **AIA SECTION 12**

Supplemental examination, **22:3**

## **AIA SECTION 13(a)**

Funding agreements, **31:2**

## **AIA SECTION 16(a)**

**Marking**, **6:3**

## **AIA SECTION 16(b)**

**False Patent Marking** (this  
index)

## **AIA SECTION 17**

Enhanced damages and advice of  
counsel, **10:3**

## **AIA SECTION 18**

**Covered Business Method  
Patents** (this index)

## **AIA SECTION 19**

Jurisdiction, **12:3**

## **AIA SECTION 20(i)(2)**

Funding agreements, **31:2**

## **AIA SECTION 21**

Payment of ALJs, **31:3**  
Travel expenses, **31:3**

## **AIA SECTION 25**

Accelerated examination, **29:3**

## AIA: A GUIDE TO PATENT LITIGATION & PROCEDURE

### **AIA SECTION 26**

Study on AIA implementation,  
**31:4**

### **AIA SECTION 27**

Study on genetic testing, **31:5**

### **AIA SECTION 28**

Patent ombudsman program, **31:6**

### **AIA SECTION 29**

Study on diversity of applicants,  
**31:7**

### **AIA SECTION 30**

Small businesses and inventors,  
**31:8**

### **AIA SECTION 31**

Study on international patent  
protection for small busi-  
nesses, **31:9**

### **AIA SECTION 32**

Pro bono program, **31:10**

### **AIA SECTION 33**

Ban on patents, **4:4**  
Human organisms, **4:2**

### **AIA SECTION 35**

Effective date, **32:2**  
Enhanced damages and advice of  
counsel, **10:4**

### **AIA SECTION 36**

Budgetary effects, **31:12**

### **AIA SECTION 37(a)**

Patent term extension, **30:3**

### **AIA SECTION 37(b)**

Patent term extension, **30:2**

### **AIA SECTION 102**

Examples of application, **2:11 to  
2:22**

### **AMERICAN INVENTOR'S PROTECTION ACT OF 1999**

Prior use defense, **8:1**

### **APPEAL AND REVIEW**

Reexaminations, ex parte  
reexaminations, **23:7**  
U.S. Patent and Trademark Office.  
**PTAB Trial Practice** (this  
index)

### **APPLICATION DATA SHEET**

Assignee filing and inventor's  
oath, **24:10**

### **ASSIGNEE FILING AND INVENTOR'S OATH**

Generally, **24:1 to 24:13**  
Amendment  
regulations, **24:4**  
statutes, **24:3**  
Applicant, **24:5**  
Application data sheet, **24:10**  
Background, **24:1**  
Congressional intent, **24:2**  
Data sheet, **24:10**  
Declaration, **24:7**  
Estoppel  
assignor, **24:11**  
licensee, **24:11**  
Historical perspective, **24:1**  
Name of inventor, **24:6**  
New regulations, **24:4**  
New statutes, **24:3**  
Oath or declaration, **24:7**  
Practice, generally, **24:4 to 24:11**  
Priority claims, **24:9**  
Substitute statements, **24:8**  
USPTO recommendations, **24:11**

### **ATTORNEYS**

Advice. **Enhanced Damages and  
Advice of Counsel** (this  
index)  
PTAB trial practice, **15:6**

### **BACKGROUND**

Accelerated examination, **29:1**  
Assignee filing and inventor's  
oath, **24:1**  
Best mode, **3:1**

## INDEX

### **BACKGROUND—Cont'd**

- Covered business method patents, **17:1**
- Deceptive intent, removal, **27:1**
- Derivation proceedings, **19:1**
- Effective dates, **32:1**
- Enhanced damages and advice of counsel, **10:1**
- False patent marking, **9:1**
- Fee setting and fees, **25:1**
- First inventor to file system, **2:1, 2:6, 2:9**
- Human organisms, **4:1**
- Inter partes review, **18:1**
- Joinder and consolidation, **13:1**
- Jurisdiction, **12:1**
- Marking, **5:1**
- Patent term extension calculation, **30:1**
- Post-grant review, **16:1**
- Post-issuance submissions, **21:1**
- Pre-issuance submissions, **20:1**
- Prior commercial use, **2:6**
- Prioritized examination, **29:1**
- Prior user defense, **8:1**
- Satellite offices, **28:1**
- Supplemental examination, **22:1**
- Venue for review of USPTO decisions, **11:1**

### **BEST MODE**

- Generally, **3:1 to 3:8**
- Applicable USPTO final rules, **3:4**
- Congressional intent, **3:2, 14:2**
- Defense, elimination from litigation, **3:5, 14:3**
- Disclosure requirement, **App 4**
- Effective date of amendments, **3:7**
- Elimination of best mode defense from litigation, **3:5, 14:3**
- Global harmonisation of patent laws, **3:1, 3:5**
- Historical perspective, **3:1**
- Litigation, best mode amendments, **3:5, 3:7**
- Other Section 112 requirements, **3:8**

### **BEST MODE—Cont'd**

- Patent prosecution, **3:5**
- Post-grant review, inapplicability, **3:6**
- Removal of consequences for violating disclosure requirement, **3:3**
- Requirement, generally, **3:1 to 3:9**

### **BIOTECHNOLOGY**

- Prior use defense, **8:1**
- 35 U.S.C. Section 282, **14:4**

### **BUDGETARY EFFECTS**

- AIA Section 36, **31:12**

### **CALCULATION**

- Patent Term Extension** (this index)

### **CASE OR CONTROVERSY**

- PTAB trial practice, **15:72**

### **CHECKLISTS**

- Covered business method patents review, **17:7**
- Derivation proceedings, **19:5**
- Inter partes review, **18:4**
- Post-grant review, **16:4**

### **CLAIMED INVENTION**

- Definition, **1:1**

### **COMMON OWNERSHIP**

- Examples of application of AIA Section 102, **2:11 to 2:22**
- Joint Research Agreement** (this index)
- Section 102(a)(2) exception, **2:7**

### **CONDITIONS**

- Fee-based revised accelerated examination, **29:6**
- Joinder and consolidation, **13:6**
- Patentability, comparison of former and current Section 102, **2:3**

### **CONGRESSIONAL INTENT**

- Generally, **2:4**
- Accelerated examination, **29:2**

## CONGRESSIONAL INTENT

### —Cont'd

Assignee filing and inventor's oath, **24:2**  
 Best mode, **3:2, 14:2**  
 Covered business method patents, **17:1**  
 Deceptive intent, removal, **27:1**  
 Derivation proceedings, **2:4, 19:2**  
 Ease of determining right to claimed invention, **2:4**  
 Effective dates, **32:1**  
 Efficiency benefits to applicants, **2:4**  
 Elimination of costly, complex interference proceedings, **2:4**  
 Enhanced damages and advice of counsel, **10:2**  
 False patent marking, **9:2**  
 Fee setting and fees, **25:1**  
 First inventor to file, **2:4**  
 Global uniformity of patent laws, **2:1, 2:4**  
 Grace period to inventors, **2:4, 2:6**  
 House Report excerpts, **App 1**  
 Human organisms, **4:1**  
 Inter partes reexamination statute, **23:2**  
 Inter partes review, **18:1**  
 Joinder and consolidation, **13:2**  
 Jurisdiction, **12:2**  
 Marking, **5:2**  
 Patent term extension calculation, **30:1**  
 Post-grant review, **16:1**  
 Post-issuance submissions, **21:2**  
 Pre-issuance submissions, **20:2**  
 Prior art, prior to filing date, **2:4**  
 Prioritized examination, **29:2**  
 Prior use defense, **8:2**  
 Progress of science and useful arts, **2:1**  
 Reexaminations, **23:2**  
 Satellite offices, **28:1**  
 Supplemental examination, **22:2**

## CONGRESSIONAL INTENT

### —Cont'd

Tax strategies, limited patentability, **5:1**  
 Venue for review of USPTO decisions, changes, **11:2**

## CONSIDERED, RECONSIDERED, OR CORRECTED

**Supplemental Examination** (this index)

## CONSOLIDATION

**Joinder and Consolidation** (this index)

## CONSTITUTIONALITY

First inventor to file system, **2:2**

## CORRECTION OF INFORMATION

**Supplemental Examination** (this index)

## COUNSEL

Advice. **Enhanced Damages and Advice of Counsel** (this index)  
 PTAB trial practice, **15:6**

## COVERED BUSINESS METHOD PATENTS

AIA Section 18, generally, **17:2**  
 Background, **17:1**  
 Checklist for review, **17:7**  
 Civil litigation, effect of CBM review, **17:11 to 17:14**  
 Congressional intent, **17:1**  
 Content of petition, **17:7**  
 Definition, **1:1**  
 Eligibility to file petition, **17:5**  
 Eligible patents, **17:4**  
 Estoppels, **17:15**  
 Expiration of provisions, **17:3**  
 Final written decisions, **17:10**  
 Petition for CBM review, **17:5 to 17:7**

## INDEX

### COVERED BUSINESS METHOD

#### PATENTS—Cont'd

- Preliminary injunctions, civil litigation, effect of CBM review, **17:14**
- Prior art against “first-to-invent” patents, **17:8**
- Prior use defense, **8:1**
- Proceedings, **17:9**
  - final written decisions, **17:10**
- Restrictions, **17:5, 17:6**
- Review, generally, **17:1 to 17:11**
- Statistics, PTAB, **17:16**
- Stay of litigation, effect of CBM review, **17:13**
- Timeliness of petition, **17:6**
- Venue, civil litigation, effect of CBM review, **17:12**

### DAMAGES

#### Enhanced Damages and Advice of Counsel (this index)

### DATA SHEET

- Assignee filing and inventor's oath, **24:10**

### DECEPTIVE INTENT, REMOVAL

- Generally, **27:1 to 27:3**
- Amended statute, **27:2**
- Background, **27:1**
- Congressional intent, **27:1**
- Elimination of defense from litigation, **14:3**
- 35 U.S.C. Section 42 revisions, **27:3**

### DECLARATORY JUDGMENT ACTIONS

- False patent marking, **9:8**

### DEFINITIONS

- Claimed invention, **1:1**
- Commercial use, **8:1**
- Competitive injury, **9:5**
- Covered business method patent, **1:1**
- Director, **1:1**

### DEFINITIONS—Cont'd

- Effective filing date, **1:1**
- Inventor, **1:1**
- Joint inventor, **1:1**
- Joint research agreement, **1:1**
- Micro entity, **1:1**
- Office, **1:1**

### DERIVATION PROCEEDINGS

- Generally, **19:1 to 19:11**
- Administrative patent judge, **19:7**
- Arbitration, **19:8**
- Background, **19:1**
- Checklist for petition, **19:5**
- Common ownership, **19:8**
- Congressional intent, **19:2**
- Date invention is made, relevance, **2:8**
- Effective date, **19:10**
- Filing petition, **19:5**
- Institution of proceeding, **19:7**
- Issued patents, derivation actions between owners, **19:9**
- Mandatory notice, **19:6**
- Post-institution of proceeding, **19:8**
- Preliminary response, **19:6**
- Proceedings, generally, **19:4**
- Public availability of Board records, **19:8**
- Responses, **19:6**
- Settlements, **19:8**
- 35 U.S.C. Section 135
  - revision, **19:3 et seq.**
  - superseded by AIA first inventor to file system, **19:2**
- 35 U.S.C. Section 291, **19:3 et seq.**

### DIRECTOR

- Definition, **1:1**

### DISCLOSURE

- Best mode disclosure requirement, **3:3, App 4**
- Examples of application of AIA Section 102, **2:11 to 2:22**

**DISCLOSURE—Cont’d**

“Publicly disclosed” identified as definition missing from AIA, **1:2**

Removal of consequences for violation of best mode disclosure requirement, **3:3**

**DISCOVERY**

Inter partes review, **18:11**

Post-grant review, **16:11**

**PTAB Trial Practice** (this index)

**EFFECTIVE DATES**

Advice of counsel, AIA provisions, **10:4**

AIA Section 35, **32:2**

Background, **32:1**

Best mode amendments, **3:7**

Congressional intent, **32:1**

Definition of effective filing date, **1:1**

Derivation proceedings, **19:10**

First inventor to file, **2:9**

Inter partes review, **18:18**

Jurisdiction provisions of AIA Section 19, **12:3**

Post-grant review, **16:17**

Provision, **32:2**

Table of AIA effective dates, **32:3**

**EFFECTIVE FILING DATE**

Definition, **1:1**

**EMBRYOS**

Unpatentability of human organism, **4:4**

**ENFORCEMENT ISSUES**

**Advice of Counsel** (this index)

**Best Mode** (this index)

Biotechnology composition of matter exception in 35 U.S.C. Section 282, **14:4**

Deceptive intent defense, **14:3**

**Enhanced Damages** (this index)

**False Patent Marking** (this index)

**ENFORCEMENT ISSUES**

—Cont’d

**Joinder and Consolidation** (this index)

**Jurisdiction** (this index)

**Prior Use** (this index)

**Venue for Review of USPTO Decisions** (this index)

**ENHANCED DAMAGES AND ADVICE OF COUNSEL**

Generally, **10:1 to 10:5**

AIA Section 17, **10:3**

AIA Section 35, **10:4**

Background to new 35 U.S.C. Section 298, **10:1**

Congressional intent, **10:2**

Discussion of new 35 U.S.C. Section 298, **10:5**

Effective date of AIA provisions on advice of council, **10:4**

Willfulness and advice of council, **10:1**

**ESTOPPELS**

Assignor, **24:12**

Inter partes review, **18:14**

Licensee, **24:13**

Post-grant review, **16:13**

Review of covered business method patents, **17:15**

**EVIDENCE**

**PTAB Trial Practice** (this index)

**EXAMINATIONS**

**Prioritized and Priority Examinations** (this index)

**Reexaminations** (this index)

**Supplemental Examination** (this index)

**EXAMPLES**

First Inventor to File, application of AIA Section 102, **2:11 to 2:22**

Prior user defense, **8:4**

Tax strategies, limited patentability, **5:3**

## INDEX

### EX PARTES REVIEW

Reexaminations (this index)

### EXPERIMENTAL USE

Prior art categories of Section 102(a)(1), **2:6**

### EXPUNGEMENT OF CONFIDENTIAL INFORMATION

PTAB trial practice, **15:69**

### FALSE PATENT MARKING

Generally, **9:1 to 9:10**

Activity that is not competitive injury, **9:5**

AIA Section 16(b)  
amendment of 35 U.S.C. Section 292, **9:3**

Constitutional challenges, **9:9**  
pending litigation, **9:4**

Background, **9:1**

Competitive injury  
activity that is not competitive injury, **9:5**

meaning, **9:5**  
pleading requirements, **9:6**  
presumption, **9:6**

Congressional intent, **9:2**

Declaratory judgment actions, **9:8**

Historical perspective, **9:1**

Pending litigation, **9:4**

Pleading requirements for competitive injury, **9:6**

Preemption of state causes of action, **9:10**

Presumption of competitive injury, **9:6**

Prudential standing to sue for false marking, **9:7**

Qui tam action, **9:1, 9:4, 9:9**

Standing  
declaratory judgment action for no false marking, **9:8**  
false marking, standing to sue, **9:7**

State causes of action, **9:10**

### FALSE PATENT MARKING

—Cont'd

Statutory standing to sue for false marking, **9:7**

35 U.S.C. Section 292, AIA statutory changes, **9:3**

### FEES, FEE SETTING AND FEE DIVERSION

Accelerated examination, fee-based revised examination provisions, **29:5, 29:6**

AIA Section 10 fee setting, **25:3**

AIA Section 11 fees, **25:4**

Amended statutes  
fee diversion, **26:2**  
fee setting, **25:2**

Background  
fee diversion, **26:1**  
fee setting, **25:1**

Congressional intent  
fee diversion, **26:1**  
fee setting, **25:1**

Fee diversion, PTO funding  
generally, **26:1 to 26:3**  
background, **26:1**  
Congressional intent, **26:1**  
35 U.S.C. Section 42 revisions, **26:3**

PTO fee funding, generally, **26:1 to 26:3**

PTO fee setting, generally, **25:1 to 25:4**

Setting of fees  
generally, **25:1 to 25:4**  
AIA Section 10 fee setting, **25:3**  
AIA Section 11 fees, **25:4**  
amended statutes, **25:2**  
background, **25:1**  
Congressional intent, **25:1**  
35 U.S.C. Section 42 revisions, **26:3**

### FETUSES AND EMBRYOS

Unpatentability of human organism, **4:4**

**FIRST INVENTOR'S DEFENSE  
ACT OF 1999**

Prior user defense, **8:1**

**FIRST INVENTOR TO FILE**

Generally, **2:1 to 2:22**

Applications, **2:9**

Congressional intent, **2:4**

Constitutionality, **2:2**

Contrast of former and current  
Section 102, **2:3**

Ease of determining right to  
claimed invention, **2:4**

Effective date, **2:9**

Examples of application of AIA  
Section 102, **2:11 to 2:22**

Former and current Section 102  
contrasted, **2:3**

Future litigation involving former  
Section 102, **2:10**

Grace period to inventors, **2:4,**  
**2:6, 2:7**

Historical perspective, **2:1, 2:6,**  
**2:9**

Litigation involving former and  
current Section 102, **2:10**

Qualification sweeps in all claims,  
**2:9**

Relevant claims for testing, **2:9**

Trigger date, **2:9**

**FUNDING AGREEMENTS**

AIA Section 3(g)(7)(A, B), **31:2**

AIA Section 13(a), **31:2**

AIA Section 20(i)(2), **31:2**

35 U.S.C. Section 202, **31:2**

**GENETIC TESTING**

AIA Section 27, study, **31:5**

**GEOGRAPHIC RESTRICTIONS**

First inventor to file, **2:6**

**GLOBAL HARMONISATION OF  
PATENT LAWS**

Best mode, **3:1, 3:5**

First inventor to file system, adop-  
tion, **2:1**

**GRACE PERIOD TO  
INVENTORS**

First inventor to file, **2:4, 2:6**

**HUMAN ORGANISMS**

Generally, **4:1 to 4:4**

AIA Section 33, **4:2**

Analysis re: ban, **4:4**

Background, **4:1**

Ban on patents, **4:2, 4:4**

Claims directed to or encompass-  
ing, **App 5**

Congressional intent, **4:1**

Fetuses and embryos, **4:4**

Historical perspective, **4:1**

Subject matter eligibility, 35

U.S.C. 101, **4:5**

Unpatentability, **4:1 to 4:5**

USPTO interpretation re: ban, **4:3**

Weldon Amendment, **4:1**

**INITIAL CONFERENCE CALL**

Inter partes review, **18:7**

Post-grant review, **16:7**

**INTERNATIONAL PATENT  
PROTECTION FOR SMALL  
BUSINESSES**

AIA Section 31, study, **31:9**

**INTER PARTES REVIEW**

Generally, **18:1 to 18:17**

AIA Section 6(a-c), generally,  
**18:1**

Background, **18:1**

Checklist for review, **18:4**

Civil litigation, relationship to,  
**18:12, 18:13**

Congressional intent, **18:1**

Discovery and trial procedure,  
**18:11**

Effective dates, **18:18**

Estoppels, **18:14**

Initial conference call, **18:7**

Institution of review, **18:6**

Intervening rights, **18:16**

Joinder of multiple proceedings,  
**18:9**



## INDEX

### INTER PARTES REVIEW

#### —Cont'd

Judicial review, **18:17**  
Multiple proceedings and joinder, **18:9**  
One month window, initial conference call, **18:7**  
Petition, **18:4**  
Preliminary response by patent owner, **18:5**  
Procedures, **18:3**  
**Reexaminations** (this index)  
Rehearing, **18:17**  
Response and amendment by patent owner, **18:8**  
Settlements, **18:15**  
Statistics, PTAB, **18:19**  
Stay of litigation, **18:12, 18:13**  
Supplemental information, **18:10**  
35 U.S.C. Sections 311 to 319, generally, **18:1**  
Three month window  
    preliminary response by patent owner, **18:5**  
    response and amendment by patent owner, **18:8**  
Trial proceedings, **18:7**  
USPTO certificate and intervening rights, **18:16**

### INTERVENING RIGHTS

Inter partes review, **18:16**  
Post-grant review, **16:15**

### INVENTOR

Definition, **1:1**

### JOINDER AND

#### CONSOLIDATION

Generally, **13:1 to 13:11**  
AIA Section 19(d), **13:3**  
Any claim, **13:8**  
Applicability of Section 299, **13:4**  
Background, **13:1**  
Conditions, **13:6**  
Congressional intent, **13:2**  
Different products, **13:11**  
Effective date of Section 299, **13:5**

### JOINDER AND

#### CONSOLIDATION—Cont'd

Federal Rules of Civil Procedure, Rules 20, 21 and 42, **13:1**  
Historical perspective, **13:1**  
Inter partes review, **18:9**  
Multidistrict litigation, **13:17**  
Multiple products/single defendant, **13:14**  
Post-grant review, **16:9**  
Pre-trial proceedings, consolidation, **13:16**  
Same industry standard, **13:12**  
Same or different products, **13:11**  
Same patent(s), **13:10**  
Same transaction, occurrence or series thereof, **13:9**  
Severance motions, **13:15**  
Specific applications, **13:9 to 13:14**  
Specific topics, **13:8**  
Table of required conditions, **13:6**  
35 U.S.C. Section 299, generally, **13:3**  
Trial proceedings, consolidation, **13:16**  
Venue, joining insignificant parties for, **13:13**  
Waiverability, **13:18**

### JOINT INVENTOR

Definition, **1:1**

### JOINT RESEARCH AGREEMENTS

Common ownership, Section 102(a)(2) exception, **2:7**  
Definition, **1:1**  
Prior art exception, **2:4**

### JUDICIAL REVIEW

Inter partes review, **18:17**  
Post-grant review, **16:16**  
**U.S. Patent and Trademark Office** (this index)

### JURISDICTION

Generally, **12:1 to 12:4**

## **JURISDICTION—Cont’d**

- AIA Section 19, **12:3**
- Background, **12:1**
- Congressional intent, **12:2**
- Discussion of AIA changes, **12:4**
- Effective date of AIA Section 19, **12:3**
- Removal and remand, **12:4**
- State court jurisdiction, **12:4**
- 28 U.S.C. Section 1295, revision by AIA Section 19(b), **12:3**
- 28 U.S.C. Section 1338, revision by AIA Section 19(a), **12:3**
- 28 U.S.C. Section 1454, new section added by AIA Section 19(c), **12:3**

## **LEAHY-SMITH AMERICA INVENTS ACT**

- Act to Correct and Improve Certain Provisions of Leahy-Smith America Invents Act, **App 7**
- Text of Act, **App 2**

## **LITIGATION**

- Best mode amendments, **3:5, 3:7**
- Covered business method patents, effect of review on civil litigation, **17:11 to 17:14**
- Declaratory judgment actions, false patent marking, **9:8**
- First inventor to file, former and current versions of Section 102, **2:10**
- Inter partes review, relationship to civil litigation, **18:12, 18:13**
- Joinder and consolidation, multidistrict litigation, **13:17**
- Pending litigation for false patent marking, AIA Section 16(b), **9:4**
- Post-grant review, relationship to civil litigation, **16:12**
- Review of covered business method patents, **17:11 to 17:14**

## **LITIGATION—Cont’d**

- Standing to sue for false marking, **9:7**
- Study of patent litigation by non-practicing entities, AIA Section 34, **31:11**

## **MARKING**

- Generally, **6:1 to 6:5**
- AIA Section 16(a), **6:3**
- Background on patent marking, **6:1**
- Congressional intent, **6:2**
- Effective date, **6:4**
- False Patent Marking** (this index)
- General comments, **6:5**
- Historical perspective, **6:1**
- Updating Web site, **6:5**
- Virtual marking, **6:2, 6:3**

## **MICRO ENTITY**

- Definition, **1:1**

## **MISMARKING**

- False Patent Marking** (this index)

## **MISTAKE**

- PTAB trial practice, **15:53**

## **MOTIONS**

- PTAB Trial Practice** (this index)

## **MULTIDISTRICT LITIGATION**

- Joinder and consolidation, **13:17**

## **NAMES**

- Assignee filing and inventor’s oath, name of inventor, **24:6**

## **OATH OR DECLARATION**

- Inventor’s oath, **24:7**

## **OFFICE**

- Defined as U.S. Patent and Trademark Office, **1:1**

## **ON SALE BAR**

- Prior art categories of Section 102(a)(1), **2:6**

## INDEX

### ORAL ARGUMENT

PTAB trial practice, **15:47**

### OTHERWISE AVAILABLE TO THE PUBLIC

Definition missing from AIA, **1:2**  
Prior art categories of Section 102(a)(1), **2:6**

### PATENT AND TRADEMARK OFFICE

U.S. Patent and Trademark Office (this index)

### PATENT OMBUDSMAN PROGRAM

AIA Section 28, **31:6**

### PATENT TERM EXTENSION

AIA Section 37(a), **30:3**  
AIA Section 37(b), **30:2**  
Amended 35 U.S.C. Section 156(d), **30:2, 30:3**  
Background, **30:1**  
Calculation of 60-day Period for Application for Patent Term Extension, **30:2**  
Congressional intent, **30:1**  
Historical perspective, **30:1**

### PAYMENT

AIA Section 21, payment of ALJs, **31:3**

### PENDING LITIGATION

False patent marking, AIA Section 16(b), **9:4**

### POST-GRANT REVIEW

Generally, **16:1 to 16:17**  
AIA Section 6(d), generally, **16:1**  
Background, **16:1**  
Best mode, inapplicability, **3:6**  
Checklist for petition, **16:4**  
Civil litigation, relationship to, **16:12**  
Congressional intent, **16:1**  
Discovery and trial procedure, **16:11**  
Effective dates, **16:17**

### POST-GRANT REVIEW—Cont'd

Estoppels, **16:13**  
Filing petition, **16:4**  
Initial conference call, **16:7**  
Institution of review, **16:6**  
Joinder of multiple proceedings, **16:9**  
Judicial review, **16:16**  
Multiple proceedings, **16:9**  
One month window, **16:7**  
Preliminary response by patent owner, **16:5**  
Procedures, **16:3**  
Rehearing, **16:16**  
Relationship to civil litigation, **16:12**  
Settlements, **16:14**  
Supplemental information, **16:10**  
35 U.S.C. Sections 321 to 329, generally, **16:2**  
Three months window  
    patent owner preliminary response, **16:5**  
    patent owner response and amendment, **16:8**  
“Trial” proceedings, **16:7**  
USPTO certificate and intervening rights, **16:15**

### POST-ISSUANCE SUBMISSIONS

Generally, **21:1 to 21:6**  
Amended statute, **21:3**  
Background, **21:1**  
Congressional intent, **21:2**  
Filing post-issue citation of art or information, **21:5**  
35 U.S.C. Section 301, **21:3**  
37 C.F.R. § 1.501, **21:4**  
USPTO use of post-issue submission, **21:6**

### PRE-ISSUANCE SUBMISSIONS

Generally, **20:1 to 20:9**  
AIA Section 8(a), **20:3**  
Amended statute, **20:3**  
Background, **20:1**  
Congressional intent, **20:2**

## **PRE-ISSUANCE SUBMISSIONS**

### **—Cont'd**

- Filing under 37 CFR Section 1.290, **20:5**
- Protests under 35 U.S.C. Section 122(c) and 37 CFR Section 1.291, **20:8**
- Statistics, USPTO, **20:9**
- Subsequent handling of 37 CFR Section 1.290, **20:7**
- Survival of protests under 35 U.S.C. Section 122(c) and 37 CFR Section 1.291, **20:8**
- Third party preissuance submissions, **20:2 et seq.**
- 35 U.S.C. Section 122, **20:3**
- 35 U.S.C. Section 122(c) protests, **20:8**
- 37 CFR Section 1.290, **20:4, 20:5**
- 37 CFR Section 1.291 protests, **20:8**
- Timing, **20:6**

## **PRELIMINARY INJUNCTIONS**

- Covered business method patents, civil litigation, effect of CBM review, **17:14**

## **PRINTED PUBLICATION**

- PTAB trial practice, proof, **15:92**
- 35 U.S.C. section 102, bar to novelty, **2:6**

## **PRIOR ART**

- Congressional intent, art prior to filing date, **2:4**
- Grace period
  - Congressional intent, **2:4**
  - earlier filed application, **2:7**
  - Section 102(a)(1), **2:6**
  - Section 102(a)(2), **2:7**
- Joint research agreement exception, **2:4**
- Published applications effective as prior art, **2:7**
- Section 102(a)(1) prior art categories and exceptions, **2:6**

## **PRIOR ART—Cont'd**

- Section 102(a)(2) prior art categories and exceptions, **2:7**
- Tax Strategies** (this index)

## **PRIORITIZED AND PRIORITY EXAMINATIONS**

- Generally, **29:1 to 29:6**
- AIA Section 11(h), **29:3**
- AIA Section 25, **29:3**
- Amended statutes, **29:3**
- Congressional intent, **29:2**
- Fee-based revised examination conditions, **29:6**
- provisions, **29:5**
- Initial conditions for fee-based revised examination, **29:6**
- Non-fee based revised examination provisions, **29:4**
- 17 C.F.R. 1.17(c), **29:6**
- 17 C.F.R. 1.102, **29:6**
- 35 U.S.C. Section 2(b), **29:3**
- Track One petitions, USPTO statistics on, **29:7**

## **PRIORITY CLAIMS**

- Assignee filing and inventor's oath, **24:9**

## **PRIORITY SYSTEM**

- First Inventor to File** (this index)

## **PRIOR USER DEFENSE**

- Generally, **8:1 to 8:4**
- AIA revisions, **8:3**
- American Inventor's Protection Act of 1999, **8:1**
- Analysis of expanded prior use defense, **8:4**
- Background, **8:1**
- Burden of proof, **8:4**
- Business methods, **8:1, 8:4**
- Change in title of defense, **8:4**
- Congressional intent, **8:2**
- Continuity, **8:1**
- Domestic commercial requirement, **8:1, 8:4**
- Examples, **8:4**

## INDEX

### **PRIOR USER DEFENSE—Cont'd**

- Expanded prior use defense, **8:4**
- First Inventor's Defense Act of 1999, **8:1**
- Good faith, **8:1, 8:4**
- Limitation on university exception, **8:4**
- Location, **8:1**
- Nonderivation requirement, **8:4**
- Nonprofit laboratory use, **8:4**
- Originality, **8:1**
- Personal defense expansion, **8:4**
- Personal defense limitation, **8:1**
- Premarket regulatory review, **8:4**
- Proof, **8:1**
- Sanctions, **8:1, 8:4**
- Site requirements, **8:4**
- Time, **8:1, 8:4**
- Type of patent, **8:1, 8:4**
- University exception, **8:4**
- USPTO report, **8:4**

### **PRO BONO PROGRAM**

- AIA Section 32, **31:10**

### **PROGRESS OF SCIENCE AND USEFUL ARTS**

- First inventor to file system, adoption, **2:1**

### **PROTECTIVE ORDERS**

- PTAB trial practice, **15:8, 15:9**

### **PTAB TRIAL PRACTICE**

- Generally, **15:1 to 15:93**
- Acceptance, petition, **15:10**
- Amending claim, motions, deadline, **15:40**
- Appeal and review
  - generally, **15:70 to 15:75**
  - burden shifting, **15:74**
  - case or controversy requirement, **15:72**
  - court review, **15:71**
  - procedural issues, **15:75**
  - standard of review, **15:73**
- Board, generally, **15:1**
- Claim construction, **15:4**

### **PTAB TRIAL PRACTICE**

#### **—Cont'd**

- Correction of mistakes, **15:53**
- Counsel, **15:6**
- Decisions on motions and petitions, **15:64 to 15:67**
- Default protective order, **15:8**
- Discovery
  - generally, **15:48 to 15:52**
  - patent owner's discovery and motion period, **15:40**
  - patent owner's further discovery period, **15:43**
  - petitioner's discovery, reply and opposition period, **15:42**
- Due date
  - 1A, motion to amend claim, **15:40**
  - 1B, patent owner's response to petition and close of discovery and motion period, **15:41**
  - 2, petitioner's discovery, reply and opposition period, **15:42**
  - 3, patent owner's further discovery period, **15:43**
  - 4, various motion deadlines, **15:44**
  - 5, reply and opposition deadlines, **15:45**
  - 6, replies to motions to exclude evidence, **15:46**
  - 7, oral argument, **15:47**
- Evidence
  - generally, **15:61, 15:62**
  - exclude evidence, motions, **15:46**
  - objections to petition evidence, **15:39**
  - ruling on petition, **15:21, 15:25**
- Final decision, **15:64 to 15:67**
- Form of petition and other filings, **15:7**
- Institution of trial, **15:16**
- Mandatory notices, preliminary proceeding, **15:5, 15:6**

## **PTAB TRIAL PRACTICE**

### **—Cont'd**

Mistake corrections, **15:53**

### **Motions**

generally, **15:56 to 15:60**

amending claim, deadline, **15:40**

decisions on motions, **15:64 to 15:67**

exclude evidence, **15:59**

joinder, **15:57**

motions to exclude evidence, replies, **15:46**

patent owner's discovery and motion period, **15:41**

strike, **15:60**

termination, **15:58**

various motion deadlines, **15:44**

Non-default protective order, **15:9**

Objections to petition evidence, **15:39**

Oral argument, **15:47**

Petition, **15:3, 15:7**

acceptance or rejection, **15:10**

claim construction, **15:4**

Preliminary proceeding, **15:3**

Printed publication, proof, **15:92**

Proof, printed publication, **15:92**

Protective orders, **15:8, 15:9**

Public availability, **15:8**

Rehearing requests, **15:68**

Rejection, petition, **15:10**

Responses by patent owner prior to trial

generally, **15:11 to 15:14**

initial disclosure, agreed, **15:14**

mandatory initial disclosure, agreed, **15:14**

preliminary response, **15:13**

Rules, generally, **15:1**

### **Ruling on petition**

institution of trial, **15:16**

institution of trial denied

generally, **15:17 to 15:37**

claim terms, **15:32**

clarity, lack of, **15:19**

## **PTAB TRIAL PRACTICE**

### **—Cont'd**

Ruling on petition—Cont'd

institution of trial denied

—Cont'd

combinations, **15:30**

conclusory testimony, **15:22**

disclaimers, statutory, **15:31**

discretion, **15:33, 15:34**

estoppel, **15:35**

evidence, **15:21, 15:25**

expert opinions, **15:24**

judicial expectations, **15:18**

obviousness analysis, **15:26**

reasonableness of expectations, **15:29**

references, **15:20, 15:27, 15:28**

sovereign immunity, **15:36**

statutory disclaimers, **15:31**

technology, **15:23**

time of petition, **15:36**

Scheduling order, **15:38**

Settlement, **15:63**

Statistics, **15:93**

Trial practice, generally, **15:2, App 3**

## **PUBLICATION**

Prior art categories of Section 102(a)(1), **2:6**

## **PUBLIC DISCLOSURE**

**Disclosure** (this index)

## **PUBLICLY DISCLOSED**

Definition missing from AIA, **1:2**

## **PUBLIC USE**

Prior art categories of Section 102(a)(1), **2:6**

## **QUALIFICATION**

First inventor to file, all claims, **2:9**

## **QUI TAM ACTION**

False Patent Marking Statute, **9:1**

## INDEX

### RECONSIDERATION OF INFORMATION

**Supplemental Examination** (this index)

### REEXAMINATIONS

Generally, **23:1 to 23:7**

AIA Section 6(a)-(c), inter partes reexamination, **23:3**

AIA Section 6(h), ex partes reexamination, **23:5**

Appeal and review, ex parte reexaminations, **23:7**

Congressional intent, **23:2**

New USPTO Rules

ex partes reexamination, **23:6**

inter partes reexamination, **23:4**

Reasonable likelihood of success, **23:2**

35 U.S.C. Sections 303 and 306, ex partes reexamination, **23:5**

35 U.S.C. Sections 312 and 313, inter partes reexamination, **23:3**

### REHEARINGS

Inter partes review, **18:17**

Post-grant review, **16:16**

PTAB trial practice, requests, **15:68**

### REMOVAL AND REMAND

Jurisdiction changes, **12:4**

### SATELLITE OFFICES

Generally, **28:1 to 28:3**

AIA provisions, **28:2**

Background, **28:1**

Congressional intent, **28:1**

Discussion of provisions, **28:3**

### SCHEDULING ORDER

PTAB trial practice, **15:38**

### SETTLEMENTS

Derivation proceedings, **19:8**

Inter partes review, **18:15**

Post-grant review, **16:14**

PTAB trial practice, **15:63**

### SMALL BUSINESSES AND INVENTORS

AIA Section 30, **31:8**

### STATE COURT JURISDICTION

Jurisdiction changes, **12:4**

### STAY OF LITIGATION

Covered business method patents, effect of CBM review, **17:13**

Inter partes review, **18:12, 18:13**

### STUDY ON AIA

#### IMPLEMENTATION

AIA Section 26, **31:4**

### SUBMISSIONS OF ART

**Post-Issuance Submissions** (this index)

**Pre-Issuance Submissions** (this index)

### SUBSTITUTE STATEMENTS

Assignee filing and inventor's oath, **24:8**

### SUPPLEMENTAL

#### EXAMINATION

Generally, **22:1 to 22:9**

AIA Section 12, **22:3**

Background, **22:1**

Benefits, **22:8**

Conclusion, **22:7**

Congressional intent, **22:2**

Content of request, **22:5**

General overview, **22:4**

New question of patentability, USPTO determination, **22:6**

New statute, **22:3**

Request, **22:5**

Statistics, USPTO, **22:9**

35 U.S.C. Section 257, **22:3**

Time for USPTO determination, **22:6**

USPTO determination, **22:6**

### SUPPLEMENTAL

#### INFORMATION

Inter partes review, **18:10**

Post-grant review, **16:10**



## **TABLES**

AIA effective dates, **32:3**  
 Patentability, table comparing former and AIA-based Section 102, **2:3**

## **TAX STRATEGIES**

Generally, **5:1 to 5:4**  
 AIA Section 14 analysis, **5:4**  
 statutory provisions, **5:2**  
 USPTO guidance, **5:3, App 6**  
 Congressional intent, **5:1**  
 Electronic tax return preparation, **5:3**  
 Examples, **5:3**  
 Limited patentability, **5:1 to 5:4**  
 Manufacturing hybrid vehicle, **5:3**  
 Payroll processing, **5:3**  
 Prior art, **5:1 to 5:4, App 6**  
 Software related inventions, **5:3**  
 Tax Deferrals, **5:3**  
 Tax reduction, **5:3**

## **THIRD PARTIES**

**Pre-Issuance Submissions** (this index)

### **35 U.S.C. SECTION 2(b)**

Accelerated examination, **29:3**

### **35 U.S.C. SECTION 42**

Deceptive intent removal, revisions of statute, **27:3**  
 Fee diversion, PTO funding, **26:3**

### **35 U.S.C. SECTION 102**

Common ownership exception, **2:7**  
 Conditions for patentability, contrast of former and current Section 102, **2:3**  
 Current Section 102, former Section 102 rewritten, **2:3**  
 Described in printed publication, bar to novelty, **2:6**  
 Disclosure by actual or joint inventor, Section 102(a)(1), **2:6, 2:7**

### **35 U.S.C. SECTION 102—Cont'd**

Experimental use, **2:6**  
 Former Section 102(a) to (g), generally, **2:3**  
 Geographic restrictions, **2:6**  
 Grace period  
     Congressional intent, **2:4**  
     disclosure by actual or joint inventor, **2:6, 2:7**  
     Section 102(a)(1), **2:6**  
     Section 102(a)(2), **2:7**  
 Joint research agreements, common ownership exception, **2:7**  
 One-year grace period, disclosure by actual or joint inventor, **2:6, 2:7**  
 On sale, bar to novelty, **2:6**  
 Otherwise available to public, bar to novelty, **2:6**  
 Printed publication, bar to novelty, **2:6**  
 Prior art  
     Section 102(a)(1) and exceptions, **2:6**  
     Section 102(a)(2) and exceptions, **2:7**  
 Prior commercial use, historical perspective, **2:6**  
 Public use, bar to novelty, **2:6**  
 Published applications effective as prior art, **2:7**  
 Section 102(a) bars  
     generally, **2:5**  
     Section 102(a)(1), prior art categories and exceptions, **2:6**  
     Section 102(a)(2), prior art categories and exceptions, **2:7**  
 Section 102(b) exceptions from bars, **2:5**  
 Statutory language, **2:5**

### **35 U.S.C. SECTION 103**

Amendment of Section 282, **2:8**  
 Obviousness before effective filing date of claimed invention, **2:8**



## INDEX

### **35 U.S.C. SECTION 104**

Repealed by AIA Section 3(d), **7:1**

### **35 U.S.C. SECTION 122**

Pre-issuance submissions, **20:3**

### **35 U.S.C. SECTION 122(c)**

#### **PROTESTS**

Pre-issuance submissions, **20:8**

### **35 U.S.C. SECTION 135**

**Derivation Proceedings** (this index)

### **35 U.S.C. SECTION 157**

Repealed by AIA Section 3(e)(1), **7:1**

### **35 U.S.C. SECTION 202**

Funding agreements, **31:2**

### **35 U.S.C. SECTION 257**

Supplemental examination, **22:3**

### **35 U.S.C. SECTION 273**

AIA revisions to prior user defense, **8:3**

### **35 U.S.C. SECTION 282**

Biotechnology composition of matter exception, **14:4**

### **35 U.S.C. SECTION 291**

**Derivation Proceedings** (this index)

### **35 U.S.C. SECTION 292**

False patent marking, AIA statutory changes, **9:3**

### **35 U.S.C. SECTION 298**

**Enhanced Damages and Advice of Counsel** (this index)

### **35 U.S.C. SECTION 299**

**Joinder and Consolidation** (this index)

### **35 U.S.C. SECTION 301**

Post-issuance submissions, **21:3**

### **35 U.S.C. SECTIONS 311 TO 319**

**Inter Partes Review** (this index)

### **35 U.S.C. SECTIONS 321 TO 329**

**Post-Grant Review** (this index)

### **37 CFR SECTION 1.290**

Pre-issuance submissions, **20:4, 20:5, 20:7**

Third party preissuance submissions, **20:4**

### **37 CFR SECTION 1.291**

#### **PROTESTS**

Pre-issuance submissions, **20:8**

### **TRACK ONE PETITIONS**

USPTO statistics on, **29:7**

### **TRAVEL EXPENSES**

AIA Section 21, **31:3**

### **TRIGGER DATE**

First inventor to file, **2:9**

### **28 U.S.C. SECTION 1295**

Jurisdiction, revision by AIA Section 19(b), **12:3**

### **UNITED STATES DISTRICT**

#### **COURT OF EASTERN**

#### **DISTRICT OF VIRGINIA**

Venue for review of USPTO decisions, **11:4**

### **UNIVERSITY PATENT**

Date invention is made, relevance, **2:8**

### **U.S. PATENT AND**

#### **TRADEMARK OFFICE**

Appellate review of USPTO actions

generally, **11:1**

#### **Venue for Review of USPTO**

##### **Decisions** (this index)

Assignee filing and inventor's oath, USPTO recommendations, **24:11**

Best mode, applicable USPTO final rules, **3:4**

Definition of Office, **1:1**

Ex partes reexamination, new USPTO Rules, **23:6**

**U.S. PATENT AND  
TRADEMARK OFFICE**

**—Cont’d**

**Fees, Fee Setting and Fee Diver-**  
**sion** (this index)

“Human organism” patent ban,  
USPTO interpretation, **4:3**

Inter partes reexamination, new  
USPTO Rules, **23:4**

Non-trial proceedings

**Post-Issuance Submissions**  
(this index)

**Pre-Issuance Submissions**  
(this index)

**Reexaminations** (this index)

**Supplemental Examination**  
(this index)

Office defined, **1:1**

**Reexaminations** (this index)

**Supplemental Examination** (this  
index)

Trial proceedings

**Covered Business Method**  
**Patents** (this index)

**Derivation Proceedings** (this  
index)

**U.S. PATENT AND  
TRADEMARK OFFICE**

**—Cont’d**

Trial proceedings—Cont’d

**Inter Partes Review** (this  
index)

**Post-Grant Review** (this index)

**PTAB Trial Practice** (this  
index)

**VENUE FOR REVIEW OF  
USPTO DECISIONS**

Generally, **11:1 to 11:4**

AIA Section 9, **11:3, 11:4**

Background to venue changes,  
**11:1**

Congressional intent in venue  
changes, **11:2**

Historical perspective to venue  
changes, **11:1**

Technical amendments relating to  
venue, **11:3**

United States District Court of  
Eastern District of Virginia,  
**11:4**

**WELDON AMENDMENT**

Unpatentability of “human organ-  
isms,” **4:1**